FDA warns BD over blood collection tubes used in Magellan’s lead testing kit


Becton Dickinson BDThe FDA issued a warning letter to Becton Dickinson & Co. (NYSE:BDX) today, citing a number of violations of federal law that it identified in an inspection of the company’s New Jersey facility.

The inspection, which was done as part of the agency’s ongoing investigation into the cause of inaccurate blood lead tests linked to Magellen Diagnostics, showed that BD marketed a significantly-modified version of its Vacutainer blood collection tube without FDA clearance or approval.

Get the full story on our sister site MassDevice.

Hear from top executives at Abbott, Google, Boston Scientific, Medtronic and more at DeviceTalks Minnesota, June 4–5 in St. Paul.

Speak Your Mind